The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19629071.
- Also identified by DOI 10.1038/nrc2676 and PMC identifier 2756045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the past decade, studies of the human tumour suppressor LKB1 have uncovered a novel signalling pathway that links cell metabolism to growth control and cell polarity. LKB1 encodes a serine-threonine kinase that directly phosphorylates and activates AMPK, a central metabolic sensor. AMPK regulates lipid, cholesterol and glucose metabolism in specialized metabolic tissues, such as liver, muscle and adipose tissue. This function has made AMPK a key therapeutic target in patients with diabetes. The connection of AMPK with several tumour suppressors suggests that therapeutic manipulation of this pathway using established diabetes drugs warrants further investigation in patients with cancer.
Medical subject headings
- AMP-Activated Protein Kinases
- Neoplasms
- Protein Kinase Inhibitors
- Protein Serine-Threonine Kinases
- Signal Transduction